

Emphysema Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

<https://marketpublishers.com/r/E04DFBA78AD6EN.html>

Date: April 2025

Pages: 135

Price: US\$ 4,850.00 (Single User License)

ID: E04DFBA78AD6EN

Abstracts

The Global Emphysema Treatment Market was valued at USD 4.7 billion in 2024 and is estimated to grow at a CAGR of 4.7% to reach USD 7.5 billion by 2034. Emphysema, a chronic respiratory condition, causes permanent damage to the alveoli in the lungs, making breathing increasingly difficult and reducing the body's ability to maintain healthy oxygen levels. Even though the disease cannot be reversed, treatment strategies focus on managing symptoms, minimizing exacerbations, and enhancing lung function to improve quality of life. The market is steadily growing as healthcare providers emphasize early intervention, chronic disease management, and improved patient outcomes.

Rising awareness about pulmonary health, advancements in non-invasive diagnostics, and wider access to respiratory therapies are also fueling growth. Innovations like telemedicine consultations for COPD patients, digital inhalers, and patient-specific rehabilitation programs are changing the way emphysema is managed. Governments and private health organizations are running extensive screening programs, encouraging patients to seek medical advice earlier. As medical technology continues to evolve, more people are receiving timely diagnoses and accessing therapies tailored to their specific needs. With an aging global population, escalating urban pollution levels, and lifestyle factors like prolonged smoking habits, the need for sophisticated emphysema treatment options is expanding worldwide.

The emphysema treatment market is gaining momentum as global healthcare systems prioritize proactive management of chronic respiratory diseases. Aging demographics are particularly susceptible to lung degeneration, and emphysema remains one of the most commonly diagnosed forms of COPD. Exposure to industrial pollutants,

occupational dust, and urban air toxins is significantly raising disease incidence across developed and emerging economies. Although smoking rates are declining in some countries, it still contributes heavily to new emphysema cases. Increased public health campaigns and widespread availability of pulmonary screenings are helping detect the condition at earlier stages, enabling timely intervention and long-term care planning.

Medication-based therapies continue to dominate the emphysema treatment landscape, accounting for 62.6% of the market share in 2024. As chronic obstructive pulmonary disease cases rise globally, pharmaceutical interventions targeting airway inflammation, bronchoconstriction, and infection prevention remain critical. Continuous drug innovations are improving lung performance and enhancing patients' day-to-day living. Expanding investments in respiratory drug development are set to accelerate future market expansion.

By disease type, the centriacinar emphysema segment generated USD 2.7 billion in 2024. This subtype, primarily linked to chronic smoking, is widespread among COPD patients. Growing public awareness of smoking-related diseases and stronger health regulations are fostering demand for centriacinar-specific therapeutic options focused on lung rehabilitation and symptom management.

The United States emphysema treatment market is forecasted to reach USD 3.2 billion by 2034. An aging population, increased rates of chronic lung diseases, comprehensive reimbursement frameworks, and better insurance penetration are driving strong adoption of both pharmaceutical treatments and non-invasive respiratory care services across the country.

Leading players in the global emphysema treatment market include Abbott Laboratories, Boehringer Ingelheim, Chiesi Farmaceutici, Olympus Corporation, Novartis, Boston Scientific Corporation, Medtronic, AstraZeneca, GlaxoSmithKline, Koninklijke Philips, Teleflex, ResMed, Baxter International, Pulmonx Corporation, and Grifols. Companies are heavily investing in R&D to bring advanced combination inhalers, long-acting bronchodilators, regenerative lung therapies, and non-invasive treatment devices to market through strategic collaborations and licensing partnerships.

Contents

CHAPTER 1 METHODOLOGY & SCOPE

- 1.1 Market scope & definitions
- 1.2 Research design
 - 1.2.1 Research approach
 - 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
 - 1.3.1 Base year calculation
 - 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
 - 1.5.1 Primary sources
 - 1.5.2 Data mining sources

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Industry 360° Synopsis

CHAPTER 3 INDUSTRY INSIGHTS

- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
 - 3.2.1 Growth drivers
 - 3.2.1.1 Increasing prevalence of chronic obstructive pulmonary disease
 - 3.2.1.2 Advancements in minimally invasive treatments
 - 3.2.1.3 Growing geriatric population
 - 3.2.2 Industry pitfalls & challenges
 - 3.2.2.1 High cost of advanced therapies and treatments
 - 3.2.2.2 Limited awareness and diagnosis in developing regions
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.6 Future market trends
- 3.7 Gap analysis
- 3.8 Porter's analysis
- 3.9 PESTEL analysis

CHAPTER 4 COMPETITIVE LANDSCAPE, 2024

- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard

CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY TREATMENT TYPE, 2021 – 2034 (\$ MN)

- 5.1 Key trends
- 5.2 Medications
 - 5.2.1 Bronchodilators
 - 5.2.2 Steroids
 - 5.2.3 Other medications
- 5.3 Surgical interventions
 - 5.3.1 Lung volume reduction surgery (LVRS)
 - 5.3.2 Bullectomy
 - 5.3.3 Lung transplantation
- 5.4 Oxygen therapy

CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY TYPE, 2021 – 2034 (\$ MN)

- 6.1 Key trends
- 6.2 Centriacinar
- 6.3 Panacinar
- 6.4 Paraseptal

CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY END USE, 2021 – 2034 (\$ MN)

- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Specialty clinics
- 7.4 Ambulatory surgical centers
- 7.5 Home care settings

CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2034 (\$ MN)

8.1 Key trends

8.2 North America

8.2.1 U.S.

8.2.2 Canada

8.3 Europe

8.3.1 Germany

8.3.2 UK

8.3.3 France

8.3.4 Spain

8.3.5 Italy

8.3.6 Netherlands

8.4 Asia Pacific

8.4.1 China

8.4.2 Japan

8.4.3 India

8.4.4 Australia

8.4.5 South Korea

8.5 Latin America

8.5.1 Brazil

8.5.2 Mexico

8.5.3 Argentina

8.6 Middle East and Africa

8.6.1 South Africa

8.6.2 Saudi Arabia

8.6.3 UAE

CHAPTER 9 COMPANY PROFILES

9.1 Abbott Laboratories

9.2 AstraZeneca

9.3 Baxter International

9.4 Boehringer Ingelheim

9.5 Boston Scientific Corporation

9.6 Chiesi Farmaceutici

9.7 GlaxoSmithKline

9.8 Grifols

- 9.9 Koninklijke Philips
- 9.10 Medtronic
- 9.11 Novartis
- 9.12 Olympus Corporation
- 9.13 Pulmonx Corporation
- 9.14 ResMed
- 9.15 Teleflex

I would like to order

Product name: Emphysema Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

Product link: <https://marketpublishers.com/r/E04DFBA78AD6EN.html>

Price: US\$ 4,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E04DFBA78AD6EN.html>